The evolving role of molecular profiling in prostate cancer: basal and luminal subtyping transcends tissue of origin

Omar Y. Mian, Rahul D. Tendulkar, Mohamed E. Abazeed


Prostate cancer is the second most common cancer in men worldwide, accounting for 15% (1.1 million) of the total new male cancer cases and 6.6% (307,000) of the total cancer deaths in men (1). In the U.S., 161,360 new cases and 26,730 deaths from prostate cancer are estimated for 2017 (2).